PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New kidney drug HSK39297 moves to Long-Term safety trial
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of HSK39297 tablets in 73 people with IgA nephropathy, a kidney disease. Participants who completed a previous study will take 200 mg daily, with a possible increase to 300 mg if urine protein remains high. The goal is to se…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 22:20 UTC
-
New drug could slow kidney disease in High-Risk patients
Disease control Recruiting nowThis study tests a new medicine called sefaxersen for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The drug aims to reduce protein in the urine and slow kidney damage. About 428 adults who are at high risk of worsening kidney disease will receive…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests an experimental drug called SHR-2173 in people with IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. About 84 adults will receive either the drug or a placebo for 48 weeks, and their kidne…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New drug YKST02 aims to tame kidney disease in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called YKST02 in 12 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug is safe and tolerable, and to check if it reduces protein in the urine, a sign of kidney damage. Particip…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 17, 2026 12:05 UTC